What's Happening?
Cytiva and Rockwell Automation have introduced the Figurate SCADA system, a supervisory control and data acquisition platform aimed at eliminating digital bottlenecks in biopharmaceutical manufacturing. This system is designed to integrate seamlessly
with various instrument vendors and modalities, providing the necessary connectivity for digital integration in modern bioprocessing. According to Matt Weaver, vice president of global industry life sciences at Rockwell, the collaboration with Cytiva is a significant step towards democratizing digital manufacturing, allowing biopharma innovators to deploy SCADA systems more efficiently and cost-effectively. The Figurate SCADA system features native interoperability with Cytiva bioprocessing equipment and Rockwell Automation’s FactoryTalk software suite, enabling seamless system integration. It also supports scalable growth from process development to commercial manufacturing without requiring system redesign, and offers cost-effective compliance with cGMP standards. The system's rapid implementation is facilitated by pre-engineered templates and modular design, which shorten deployment and validation timelines.
Why It's Important?
The launch of the Figurate SCADA system is crucial for the biopharmaceutical industry, which faces increasing pressure to accelerate production timelines while maintaining high standards of data integrity and operational efficiency. By providing a unified digital control layer, the system addresses the common issue of equipment fragmentation, which often leads to operational silos and manual workarounds. This integration reduces the risk of human error, accelerates technology transfer, and supports reliable scale-up as manufacturing processes become more complex. The system's ability to enhance operational insight through centralized alarms, real-time monitoring, and tailored batch reporting is particularly beneficial for biomanufacturers transitioning from research and development to clinical scale production. As the demand for next-generation process control systems grows, the Figurate SCADA system positions itself as a vital tool for biopharma companies aiming to adopt data-driven process intensification and continuous manufacturing.
What's Next?
The introduction of the Figurate SCADA system is expected to prompt further advancements in digital manufacturing within the biopharmaceutical sector. As more companies adopt this technology, there may be increased collaboration between equipment manufacturers and software developers to enhance system capabilities and integration. Additionally, the system's success could lead to broader adoption of similar digital solutions across other sectors of the pharmaceutical industry, potentially driving innovation and efficiency improvements. Stakeholders, including biopharma companies and regulatory bodies, will likely monitor the system's impact on manufacturing processes and compliance standards closely. The ongoing evolution of digital manufacturing technologies may also influence future regulatory guidelines and industry best practices.
